---
title: "BMO Maintains Buy Rating and $190 Price Target on Protagonist Therapeutics, Citing Icotyde Potential and Pipeline Catalysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305068774.md"
description: "BMO Capital analyst Evan Seigerman maintained a Buy rating on Protagonist Therapeutics with a $190 price target, citing encouraging Icotyde results in psoriatic arthritis and potential pipeline catalysts. UBS also maintained a Buy rating with an $184 price target."
datetime: "2026-11-10T18:06:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305068774.md)
  - [en](https://longbridge.com/en/news/305068774.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305068774.md)
generator: "portal-rs"
---

# BMO Maintains Buy Rating and $190 Price Target on Protagonist Therapeutics, Citing Icotyde Potential and Pipeline Catalysts

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Protagonist Therapeutics, retaining the price target of $190.00.

Evan Seigerman has given his Buy rating due to a combination of factors, including encouraging Icotyde results in psoriatic arthritis, which broaden the drug’s potential beyond psoriasis. Although its joint-response measures did not surpass Skyrizi’s, the oral formulation, lack of new safety concerns, and meaningful activity could support adoption, especially among patients reluctant to use injections. That convenience may help Icotyde gain share over time while preserving a sizeable commercial opportunity.

Additional upside may come from the company’s development pipeline and upcoming milestones, including further PsA data, launch execution for Icotyde and Mimrylo, and clinical progress for its oral IL-17 program. These catalysts could strengthen future royalty income and demonstrate the value of Protagonist’s peptide platform across immunology and hematology. Against this backdrop, BMO keeps its price target unchanged at $190, supporting the Buy recommendation.

In another report released today, UBS also maintained a Buy rating on the stock with a $184.00 price target.

### Related Stocks

- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)

## Related News & Research

- [PTGX: Partnered launches fund a growing oral peptide pipeline, with key decisions due in 2027](https://longbridge.com/en/news/305797284.md)
- [Protagonist Therapeutics (PTGX) Is Back In The Spotlight, What Is Catching Attention?](https://longbridge.com/en/news/303608199.md)
- [Protagonist Therapeutics, Inc. $PTGX Shares Sold by Moody Aldrich Partners LLC](https://longbridge.com/en/news/303539027.md)
- [Protagonist Therapeutics Swings to Q3 Net Income of $220.02 Million](https://longbridge.com/en/news/304525865.md)
- [Arista Networks (ANET) Dropped, But What Is The Market Weighing Now?](https://longbridge.com/en/news/306371748.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**